[1] 李丰章,邹南安,胡含明,等.低剂量CT与4肿瘤标记物联合检测对肺癌高危人群筛查的研究[J].江西医药,2015,50(5):384-387. [2] BONNEY A, MALOUF R, MARCHAL C, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality[J].Cochrane Database Syst Rev,2022,8(8):CD013829. [3] National Lung Screening Trial Research Team, ABERLE D R, ADAMS A M, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med,2011,365(5):395-409. [4] 陈聚兴,高中博,伍尚剑,等.MRI联合CEA、CYFRA21-1检测对早期肺癌的诊断价值[J].检验医学与临床,2020,17(3):368-370. [5] PATEL V K, NAIK S K, NAIDICH D P, et al.A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: Part 1: Radiologic characteristics and imaging modalities[J].Chest,2013,143(3):825-839. [6] 迟静,刘伟.血清肿瘤标志物PRO-GRP、NSE、CEA、CYFRA21-1及SCC对肺癌早期诊断的价值[J].牡丹江医学院学报,2023,44(6):50-54. [7] 李馥郁,田春艳,李淘淘.血清CEA、NSE、PTN水平检测诊断早期肺癌的应用价值[J].分子诊断与治疗杂志,2022,14(3):479-482. [8] 洪永灯,黄旭苗.血清NSE、CYFRA21-1、CEA、SCC联合检测在肺癌早期诊断中的应用价值分析[J].中国医药科学,2024,14(5):157-160. [9] 孙洪帅,朱华,高海燕,等.肿瘤标志物SCC-Ag、CEA、CYFRA21-1和D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J].吉林大学学报(医学版),2018,44(5):1020-1024. [10] HE Y, SHI J, SCHMIDT B, et al.Circulating Tumor cells as a biomarker to assist molecular diagnosis for early stage non-small cell lung cancer[J]. Cancer Manag Res,2020,12:841-854. [11] DUAN G C, ZHANG X P, WANG H E, et al.Circulating tumor cells as a screening and diagnostic marker for early-stage non-small cell lung cancer[J]. Onco Targets Ther,2020,13:1931-1939. [12] 万玲玲. 循环肿瘤细胞与代谢组学的多元分析在早期非小细胞肺癌诊断中的应用价值[D].石家庄:河北医科大学,2021. [13] ROVIARO G, REBUFFAT C, VAROLI F, et al.Videoendoscopic pulmonary lobectomy for cancer[J].Surg Laparosc Endosc,1992,2(3):244-247. [14] 王少冰. 早期系统性肺康复训练在老年肺癌VATS肺叶切除术后ERAS模式下的临床应用[D].蚌埠:蚌埠医学院,2021. [15] KWON S T, ZHAO L, REDDY R M, et al.Evaluation of acute and chronic pain outcomes after robotic,video-assisted thoracoscopic surgery,or open anatomic pulmonary resection[J].J Thorac Cardiovasc Surg,2017,154(2):652-659,e1. [16] 王若峥,秦永辉,尹勇,等.3D-CRT联合主动脉呼吸控制主体定向放射治疗剂量学分析[J].中华肿瘤防治杂志,2013,20(16):1240-1244. [17] 张保义,李建斌,聂鲁栋.三种放疗方式治疗早期非小细胞肺癌的剂量学比较[J].临床医药文献电子杂志,2015,2(4):598-599. [18] 周云泷,许敬辉,杨涛,等.早期非小细胞肺癌治疗计划中IMRT与VMAT单双拉弧的剂量学对比[J].现代肿瘤医学,2019,27(4):646-649. [19] 汪波. 吉非替尼靶向治疗联合常规化疗治疗晚期非小细胞肺癌的效果观察[J].中国冶金工业医学杂志,2022,39(6):638-639. [20] 梁剑毅,卢志文,黄宪平,等.克唑替尼或吉非替尼联合GP方案治疗晚期非小细胞肺癌患者对比分析[J].内科,2022,17(2):172-175,219. [21] 梁任隆,彭小东,余倩如,等.联合抗PD-1/PD-L1组合策略在肺癌治疗中的研究进展[J].中国老年学杂志,2020,40(21):4687-4691. [22] 费苏鹏,郑盛弘,李思晨,等.使用PD-1抑制剂后早期炎性细胞因子升高对预测非小细胞肺癌患者疗效的影响[J].现代实用医学,2023,35(10):1337-1340. [23] HIRSCH F R, MCELHINNY A, STANFORTH D, et al.PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project[J]. J Thorac Oncol,2017,12(2):208-222. [24] 唐江洪,雷晓红,黄宇香,等.基于血清CEA、GPX3、CXCL9构建非小细胞肺癌患者根治术后早期复发转移的预测模型[J].现代生物医学进展,2024,24(10):1941-1945. [25] 刘鸿翔,吴涛,刘懿,等.Pentraxin-3、CYFRA21-1、TTF-1的表达与非小细胞肺癌术后早期复发的关系[J].基因组学与应用生物学,2017,36(3):1128-1133. [26] OU S H, ZELL J A, ZIOGAS A, et al.Prognostic factors for survival of stage I nonsmall cell lung cancer patients:A population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003[J].Cancer,2007,110(7):1532-1541. [27] TAYLOR M D, LAPAR D J, THOMAS C J, et al.Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer[J]. Ann Thorac Surg[J].2013,96(4):1163-1170. [28] NERI S, YOSHIDA J, ISHII G, et al.Prognostic impact of microscopic vessel invasion and visceral pleural invasion in non-small cell lung cancer: a retrospective analysis of 2 657 patients[J].Ann Surg,2014,260(2):383-388. [29] IZAR B, SEQUIST L, LEE M, et al.The impact of EGFR mutation status on outcomes in patients with resected stage Ⅰ non-small cell lung cancers[J]. Ann Thorac Surg[J].2013,96(3):962-968. [30] MATSUMOTO Y, KAWAGUCHI T, WATANABE M, et al.Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected,EGFR-mutated,non-small cell lung cancer[J]. BMC Cancer,2022,22(1):775. [31] LIANG H, HUANG J, WANG B, et al.The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer[J].J Thorac Dis,2018,10(Suppl 7):S838-S845. |